Dr. Robert Avery of California Retina Consultants reviews the latest status of gene therapy for AMD and DR.

Many drugs are currently being investigated in attacking or supplementing the complement cascade for the treatment of geographic atrophy. We review, with the help of Dr. Johanna Seddon, Professor of Ophthalmology, University of Massachusetts Medical Center the basic biology that underlies these treatments, and assess their clinical potential.

We interview Dr. Caroline Baumal, Professor Of Ophthalmology at New England Eye Center and the Tufts University School of Medicine and we review clinical applications and safety results of brolucizumab.

Dr. Linda Lam, Professor of Ophthalmology at the USC Roski Eye Institute talks about augmented reality for low vision and unique surgical applications.

Dr Barone describes the mission of Gemini and discusses recent preliminary data from the ongoing Phase 2a REGATTA study

We knew that anti-VEGF therapy favorably affected the natural history of moderate or severe  nonproliferation retinopathy. As a result of DRCR network Protocol W, we now know that careful observation with treatment of complications as they develop produces visual acuity results at 2 years similar to prophylactic therapy.

Dr. Dilsher Dhoot discusses patient outcomes in the PANORAMA trial looking at areas of non perfusion.

Dr. Jamie Dananberg, Chief Medical Officer of Unity Biotechnology discusses their strategy of selectively targeting senescent retinal vascular endothelial cells for a more long lasting effect on altering the pathophysiology of diabetic eye disease.

A Real World Clinical Trial Employing AI

Dr. Anat Loewenstein presents data demonstrating the effectiveness of the Notal Home OCT System with artificial intelligence for real world monitoring of eyes undergoing anti-VEGF therapy.

Dr. Usha Chakravarthy, Professor of Ophthalmology, Queen's University Belfast presents characteristics of macular neovascularization at its earliest diagnosis.